A review of clinical trials found cannabinoids useful for neuropathic pain and MS spasticity, and proposed an algorithm to help physicians decide when to recommend cannabis.
Read this if you are a patient or physician wanting clinical guidance on medical cannabis.
First practical prescribing algorithm for medical cannabis
What the researchers found
This review summarized the growing clinical trial evidence for medical cannabis, focusing on recent trials of smoked and vaporized marijuana as well as botanical extracts. The strongest evidence supported cannabinoids for neuropathic pain management and MS spasticity.
The authors noted that the understanding of THC and cannabinoid mechanisms had advanced significantly, providing a scientific basis for therapeutic use. They presented a clinical algorithm for physicians to determine whether cannabis might be appropriate for individual patients, weighing benefits against risks.
The review positioned medical cannabis as a legitimate therapeutic option in jurisdictions where it was permitted, while acknowledging that, like all medications, it required careful benefit-risk assessment.
Why it matters
By providing a practical prescribing algorithm, this review moved the conversation from "should cannabis be medical?" to "how should physicians use it?" This was a significant shift toward treating cannabis as a medicine requiring clinical judgment.
The numbers in context
Strongest evidence: neuropathic pain and MS spasticity. Clinical algorithm provided for physician decision-making.
How the study worked
Narrative review of recent clinical trials with smoked/vaporized marijuana and cannabis extracts. Developed a clinical decision algorithm for physician guidance.
What this study cannot tell us
Narrative review without systematic methodology. The clinical algorithm, while practical, was not validated in clinical practice. Evidence was still emerging and limited for most indications beyond pain and spasticity.
How to read the evidence
Narrative review with clinical algorithm. Synthesizes trial evidence pragmatically but is not a systematic review.
When this study was published
Published in 2012. Medical cannabis clinical guidance has expanded considerably since, with more conditions and formulations studied.
The bigger picture
The gap between legal availability and clinical guidance left physicians unprepared. This review, published in a neurology journal, helped fill that gap by synthesizing evidence and providing actionable guidance.
Questions still open
- Does the prescribing algorithm improve clinical outcomes compared to unguided prescribing? Should cannabis be treated like any other prescription medication in terms of monitoring? What evidence thresholds should trigger updates to the algorithm?
Common questions
What conditions have the best evidence for medical cannabis?
How do doctors decide whether to recommend cannabis?
Read the original research
Medical marijuana: clearing away the smoke.
The open neurology journal, 6, 18-25
Citation
Grant, Igor; Atkinson, J Hampton; Gouaux, Ben; Wilsey, Barth. (2012). Medical marijuana: clearing away the smoke.. The open neurology journal, 6, 18-25. https://doi.org/10.2174/1874205X01206010018
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk